Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)

Table 1 Baseline demographics and characteristics of the participants

Variables	Analyzed subjects (N = 50)
Age, years	70.5 ± 11.0
Male	38 (76.0)
Body mass index, kg/m²	24.7 ± 4.0
Systolic blood pressure, mmHg	131.2 ± 17.0
Diastolic blood pressure, mmHg	75.0 ± 11.3
Serum uric acid, mg/dL	8.5 ± 1.2
Active gouty arthritis	0 (0.0)
Hypertension	50 (100.0)
Dyslipidemia	37 (74.0)
Diabetes	19 (38.0)
Ischemic heart disease	16 (32.0)
Heart failure	10 (20.0)
Stroke	0 (0.0)
Medications
ACE inhibitor or ARB	44 (88.0)
Calcium channel blocker	25 (50.0)
β-blocker	31 (62.0)
Diuretic	19 (38.0)
SGLT2 inhibitor	13 (26.0)
Statin	34 (68.0)
Ezetimibe	9 (18.0)
Anti-platelet	16 (32.0)
Previous* use of urate-lowering agent	13 (26.0)

Data are expressed as mean ± standard deviation or number (percentage)
*At least 27 days before the initiation of dotinurad
ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; SGLT2: sodium-glucose cotransporter 2

ISSN: 2047-783X